Evidence map›Paper›PMID 28494242›Full record

ArticleCell host & microbe2017

Pseudomonas aeruginosa Effector ExoS Inhibits ROS Production in Human Neutrophils.

Chairut Vareechon, Stephanie Elizabeth Zmina, Mausita Karmakar, Eric Pearlman, Arne Rietsch

Open access · bronzeAbstract read
In one paragraph

Article in Cell host & microbe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 114 citations in OpenAlex.

  1. Infection and immunity · 2026
    Article
  2. Infection and immunity · 2026
    Article
  3. Characterization of two exoUBMC microbiology · 2026
    Article
  4. Article
  5. Article
  6. The small non-coding RNA sRNA102 regulatesFrontiers in cellular and infection microbiology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Frontiers in medicine · 2025
    Article
  15. Article
  16. Beyond Antibiotics: What the Future Holds.Antibiotics (Basel, Switzerland) · 2024
    Review
  17. Assessing the Potential ofACS pharmacology & translational science · 2024
    Article
  18. Article
  19. Evidence for intracellularJournal of bacteriology · 2024
    Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chairut VareechonDepartment of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Ophthalmology, Case Western Reserve University, Cleveland, OH 44106, USA.
Stephanie Elizabeth ZminaDepartment of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Mausita KarmakarDepartment of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106, USA.
Eric PearlmanDepartment of Ophthalmology, University of California, Irvine, CA 92612, USA; Department of Physiology and Biophysics, University of California, Irvine, CA 92612, USA.
Arne RietschDepartment of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA. Electronic address: arne.rietsch@case.edu.
Case Western Reserve University · USUniversity of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
TISSUE CULTURE AND HYBRIDOMA MODULEP30EY011373 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI Irina A Pikuleva · 1997 to 2026
$17.7M
Toll Like Receptors in Bacterial KeratitisR01EY014362 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI GEORGE R DUBYAK, Eric Pearlman · 2003 to 2026
$8.7M
VISUAL SCIENCES TRAINING PROGRAMT32EY007157 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI Johannes Friedrich von Lintig · 2000 to 2026
$5.5M
P. aeruginosa type III secreted effectors in corneal diseaseR01EY022052 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI RIETSCH, ARNE · 2012 to 2019
$3.1M
NCATS NIH HHS UL1 TR001414NEI NIH HHS P30 EY011373NEI NIH HHS R01 EY014362NEI NIH HHS R01 EY022052NEI NIH HHS T32 EY007157
6 · The paper itself

Abstract

Neutrophils are the first line of defense against bacterial infections, and the generation of reactive oxygen species is a key part of their arsenal. Pathogens use detoxification systems to avoid the bactericidal effects of reactive oxygen species. Here we demonstrate that the Gram-negative pathogen Pseudomonas aeruginosa is susceptible to reactive oxygen species but actively blocks the reactive oxygen species burst using two type III secreted effector proteins, ExoS and ExoT. ExoS ADP-ribosylates Ras and prevents it from interacting with and activating phosphoinositol-3-kinase (PI3K), which is required to stimulate the phagocytic NADPH-oxidase that generates reactive oxygen species. ExoT also affects PI3K signaling via its ADP-ribosyltransferase activity but does not act directly on Ras. A non-ribosylatable version of Ras restores reactive oxygen species production and results in increased bacterial killing. These findings demonstrate that subversion of the host innate immune response requires ExoS-mediated ADP-ribosylation of Ras in neutrophils.

Indexed as

ADP Ribose TransferasesADP-RibosylationAnimalsBacterial ToxinsColony Count, MicrobialEpitheliumEyeFemaleGTPase-Activating ProteinsHumansImmunity, InnateMice, Inbred C57BLNADPH OxidasesNeutrophilsPhagocytosisPhosphatidylinositol 3-KinasesADP Ribose TransferasesBacterial Toxinsexoenzyme SExoT protein, Pseudomonas aeruginosaGTPase-Activating ProteinsNADPH OxidasesPhosphatidylinositol 3-Kinasesras ProteinsReactive Oxygen SpeciesType III Secretion Systemseffector functionkeratitisT3SStype III secretion

Identifiers

PMID28494242
PMCPMC5478421
OpenAlexW2612188981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.